Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — VialBase Research
high
- 26% reduction in MACE with semaglutide vs placebo
- Significant reductions in nonfatal stroke and nonfatal MI
- HbA1c reduction of 0.7-1.0% vs placebo
Summary
SUSTAIN-6 was the cardiovascular outcomes trial (CVOT) for subcutaneous semaglutide in patients with type 2 diabetes at high cardiovascular risk. Over 2 years, semaglutide significantly reduced major adverse cardiovascular events (MACE) compared to placebo, establishing cardiovascular benefit beyond glucose control.
Key Findings
- 26% reduction in 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke): HR 0.74 (95% CI 0.58-0.95)
- 39% reduction in nonfatal stroke
- 26% reduction in nonfatal MI (not individually significant)
- Significant HbA1c reductions (0.7% with 0.5mg, 1.0% with 1.0mg vs placebo)
- Body weight reduction of 2.9-4.3 kg vs placebo
- Retinopathy complications more frequent with semaglutide (3.0% vs 1.8%)
Methodology
Double-blind, placebo-controlled CVOT in 3,297 patients with type 2 diabetes and established CVD or CV risk factors. Randomized to semaglutide 0.5mg, 1.0mg, or matching placebo weekly for 104 weeks. Primary endpoint: first occurrence of 3-point MACE.
Limitations
- Pre-approval trial — designed for noninferiority, though superiority was achieved
- Retinopathy signal requires monitoring (likely related to rapid glycemic improvement)
- CV death component not individually significant
- Population limited to T2DM with established/high CV risk
- Lower semaglutide doses than those used for weight management (2.4mg)
Relevance to Content
Critical trial for positioning semaglutide as more than a weight loss drug. The cardiovascular benefit adds a compelling health argument beyond aesthetics. Important for content addressing safety concerns or discussing semaglutide for patients with metabolic/cardiovascular risk.
See Also
- Parent compound: Semaglutide